309 related articles for article (PubMed ID: 36618375)
1. Neuroinflammation in Huntington's disease: From animal models to clinical therapeutics.
Jia Q; Li S; Li XJ; Yin P
Front Immunol; 2022; 13():1088124. PubMed ID: 36618375
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation in Huntington's Disease: A Starring Role for Astrocyte and Microglia.
Saba J; Couselo FL; Bruno J; Carniglia L; Durand D; Lasaga M; Caruso C
Curr Neuropharmacol; 2022; 20(6):1116-1143. PubMed ID: 34852742
[TBL] [Abstract][Full Text] [Related]
3. Inflammation in Huntington's disease: A few new twists on an old tale.
Valadão PAC; Santos KBS; Ferreira E Vieira TH; Macedo E Cordeiro T; Teixeira AL; Guatimosim C; de Miranda AS
J Neuroimmunol; 2020 Nov; 348():577380. PubMed ID: 32896821
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
5. Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies.
Rocha NP; Ribeiro FM; Furr-Stimming E; Teixeira AL
Mediators Inflamm; 2016; 2016():8653132. PubMed ID: 27578922
[TBL] [Abstract][Full Text] [Related]
6. Naïve Huntington's disease microglia mount a normal response to inflammatory stimuli but display a partially impaired development of innate immune tolerance that can be counteracted by ganglioside GM1.
Steinberg N; Galleguillos D; Zaidi A; Horkey M; Sipione S
J Neuroinflammation; 2023 Nov; 20(1):276. PubMed ID: 37996924
[TBL] [Abstract][Full Text] [Related]
7. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
8. Deterioration of neuroregenerative plasticity in association with testicular atrophy and dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis in Huntington's disease: A putative role of the huntingtin gene in steroidogenesis.
Selvaraj K; Manickam N; Kumaran E; Thangadurai K; Elumalai G; Sekar A; Radhakrishnan RK; Kandasamy M
J Steroid Biochem Mol Biol; 2020 Mar; 197():105526. PubMed ID: 31715317
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease: new frontiers for molecular and cell therapy.
Melone MA; Jori FP; Peluso G
Curr Drug Targets; 2005 Feb; 6(1):43-56. PubMed ID: 15720212
[TBL] [Abstract][Full Text] [Related]
12. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
Wang CE; Li S; Li XJ
Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
[TBL] [Abstract][Full Text] [Related]
13. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
14. The choreography of neuroinflammation in Huntington's disease.
Crotti A; Glass CK
Trends Immunol; 2015 Jun; 36(6):364-73. PubMed ID: 26001312
[TBL] [Abstract][Full Text] [Related]
15. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
16. Prospects for neuroprotective therapies in prodromal Huntington's disease.
Chandra A; Johri A; Beal MF
Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
[TBL] [Abstract][Full Text] [Related]
17. A novel Huntington's disease mouse model to assess the role of neuroinflammation on disease progression and to develop human cell therapies.
Dahlenburg H; Cameron D; Yang S; Bachman A; Pollock K; Cary W; Pham M; Hendrix K; White J; Nelson H; Deng P; Anderson JS; Fink K; Nolta J
Stem Cells Transl Med; 2021 Jul; 10(7):1033-1043. PubMed ID: 33710799
[TBL] [Abstract][Full Text] [Related]
18. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
19. Neurodegenerative processes in Huntington's disease.
Bano D; Zanetti F; Mende Y; Nicotera P
Cell Death Dis; 2011 Nov; 2(11):e228. PubMed ID: 22071633
[TBL] [Abstract][Full Text] [Related]
20. Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.
Paldino E; Fusco FR
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
